Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2013 - 2018)
Crescent Biopharma (CBIO) posted quarterly Non-Current Deffered Revenue of $611623.0 for Q4 2018, down 13.49% year-over-year from $707003.0 in Q4 2017, and down 16.49% quarter-over-quarter from $732387.0 in Q3 2018.
Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2013 - 2018) Analysis & Trends
Crescent Biopharma (CBIO) has reported Non-Current Deffered Revenue for 6 consecutive years, with $611623.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 13.49% year-over-year to $611623.0; the TTM figure through Dec 2018 stood at $611623.0 (down 13.49% YoY), while the FY2018 annual figure was $611623.0, down 13.49% from the prior year.
- Non-Current Deffered Revenue slipped to $611623.0 in Q4 2018 per CBIO's latest filing, from $732387.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $922824.0 in Q3 2016 and bottomed at $9709.0 in Q3 2014.
- Historically, Non-Current Deffered Revenue has averaged $499320.4 across 5 years, with a median of $707003.0 in 2017.
- Annual changes were most pronounced in 2015 — Non-Current Deffered Revenue slipped 27.5% — and 2016, when it jumped 3028.67%.
- Crescent Biopharma's Non-Current Deffered Revenue stood at $97012.0 in 2014, then jumped by 151.15% to $243647.0 in 2015, then soared by 209.29% to $753579.0 in 2016, then dropped by 6.18% to $707003.0 in 2017, then dropped by 13.49% to $611623.0 in 2018.
- Business Quant data shows CBIO's Non-Current Deffered Revenue at $611623.0 in Q4 2018, $732387.0 in Q3 2018, and $750382.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 611,623.00 |
| Sep 30, 2018 | 732,387.00 |
| Jun 30, 2018 | 750,382.00 |
| Mar 31, 2018 | 767,706.00 |
| Dec 31, 2017 | 707,003.00 |
| Sep 30, 2017 | 801,058.00 |
| Jun 30, 2017 | 742,584.00 |
| Mar 31, 2017 | 754,055.00 |
| Dec 31, 2016 | 753,579.00 |
| Sep 30, 2016 | 841,426.00 |
| Jun 30, 2016 | 799,478.00 |
| Mar 31, 2016 | 250,143.00 |
| Dec 31, 2015 | 243,647.00 |
| Sep 30, 2015 | 186,526.00 |
| Jun 30, 2015 | 28,155.00 |
| Dec 31, 2014 | 97,012.00 |
| Sep 30, 2014 | 9,709.00 |
| Jun 30, 2014 | 38,837.00 |
| Mar 31, 2014 | 67,785.00 |
| Dec 31, 2013 | 96,756.00 |